-
公开(公告)号：US20200079851A1
公开(公告)日：2020-03-12
申请号：US16678049
申请日：2019-11-08
Inventor： Chengcheng ZHANG , Mi DENG , Wei XIONG , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Junke ZHENG
IPC: C07K16/28 , G01N33/574 , C07K16/30 , A61K45/06 , A61K39/395 , A61P35/02 , C12N15/113
Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
-
公开(公告)号：US20180066066A1
公开(公告)日：2018-03-08
申请号：US15643690
申请日：2017-07-07
Inventor： Ningyan ZHANG , Zhiqiang AN
IPC: C07K16/32 , G01N33/574 , A61F7/10 , A61N5/10
CPC classification number: C07K16/32 , A61F7/10 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57484 , G01N33/57492
Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
-
公开(公告)号：US20240392001A1
公开(公告)日：2024-11-28
申请号：US18691249
申请日：2022-09-13
Inventor： Zhiqiang AN , Ningyan ZHANG , Peng ZHAO
IPC: C07K16/28
Abstract: Isolated or recombinant anti-LILRB2 monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as Alzheimer's Disease. In further aspects, the LILRB2-binding antibodies can affect cellular signaling mediated through at least the oA and PS-mediated TREM2 and LILRB2 co-ligation signaling pathway and can be used to modulate microglia function.
-
公开(公告)号：US20240294670A1
公开(公告)日：2024-09-05
申请号：US17996854
申请日：2021-04-21
Inventor： Cynthia JU , Jongmin JEONG , Zhao SHAN , Leike LI , Ningyan AN , Zhiqiang AN
CPC classification number: C07K16/40 , A61K39/4631 , A61K45/06 , A61P35/00 , A61K2039/505 , A61K2239/13 , C07K2317/11 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/565
Abstract: Provided herein are antibodies binding to CHI3L1 and the uses of the antibodies in detecting and treating cancer and for treating hepatotoxicity.
-
公开(公告)号：US20230130372A1
公开(公告)日：2023-04-27
申请号：US17757510
申请日：2020-12-17
Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM , THE GEORGE WASHINGTON UNIVERSITY
Inventor： Ningyan ZHANG , Zhiqiang AN , Hui DENG , Xiujie SUN , Rong LI
Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer. Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to DDR1. In certain embodiments, the antibody or antigen-binding fragment, when bound to DDR1, modulates the activity of DDR1, i.e., suppresses DDR1.
-
Patent Agency Ranking
公开(公告)号：US20220267415A1
公开(公告)日：2022-08-25
申请号：US17671837
申请日：2022-02-15
Inventor： Zhiqiang KU , Xuping XIE , Paul HINTON , Ningyan ZHANG , Bruce KEYT , Dean NG , Stephen CARROLL , Pei-Yong SHI , Zhiqiang AN
Abstract: This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).
-
公开(公告)号：US20200024333A1
公开(公告)日：2020-01-23
申请号：US16244097
申请日：2019-01-09
Inventor： Philipp Erich SCHERER , Jiyoung PARK , Zhiqiang AN
IPC: C07K16/18 , A61K33/24 , A61K39/395 , A61K31/555
Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
-
公开(公告)号：US20190338026A1
公开(公告)日：2019-11-07
申请号：US16475223
申请日：2018-01-02
Inventor： X. Charlene LIAO , Qiang LIU , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Chengcheng ZHANG , Mi DENG , Jingjing XIE
Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
-
公开(公告)号：US20250115546A1
公开(公告)日：2025-04-10
申请号：US18809438
申请日：2024-08-20
Inventor： Kyoji TSUCHIKAMA , Yasuaki ANAMI , Chisato TSUCHIKAMA , Ningyang ZHANG , Zhiqiang AN
IPC: C07C247/04 , A61K31/40 , A61K45/06 , A61K47/68 , A61P35/00 , C07D209/20 , C07D403/12
Abstract: In one aspect, the present disclosure provides compounds of the formula: wherein the variables are as defined herein.
In another aspect, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.-
公开(公告)号：US20240383999A1
公开(公告)日：2024-11-21
申请号：US17995214
申请日：2021-04-01
Inventor： Ningyan ZHANG , Zhiqiang AN , Zhiqiang KU , Hui DENG , Lingegowda S MANGALA , Anil K. SOOD
Abstract: Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.037 seconds)
